1. Home
  2. RVYL vs MYNZ Comparison

RVYL vs MYNZ Comparison

Compare RVYL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVYL
  • MYNZ
  • Stock Information
  • Founded
  • RVYL 2007
  • MYNZ 2021
  • Country
  • RVYL United States
  • MYNZ Germany
  • Employees
  • RVYL N/A
  • MYNZ N/A
  • Industry
  • RVYL Professional Services
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVYL Consumer Discretionary
  • MYNZ Health Care
  • Exchange
  • RVYL Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • RVYL 13.7M
  • MYNZ 9.8M
  • IPO Year
  • RVYL N/A
  • MYNZ 2021
  • Fundamental
  • Price
  • RVYL $1.76
  • MYNZ $0.38
  • Analyst Decision
  • RVYL Hold
  • MYNZ Buy
  • Analyst Count
  • RVYL 1
  • MYNZ 2
  • Target Price
  • RVYL N/A
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • RVYL 45.4K
  • MYNZ 1.4M
  • Earning Date
  • RVYL 08-12-2024
  • MYNZ 08-13-2024
  • Dividend Yield
  • RVYL N/A
  • MYNZ N/A
  • EPS Growth
  • RVYL N/A
  • MYNZ N/A
  • EPS
  • RVYL N/A
  • MYNZ N/A
  • Revenue
  • RVYL $71,352,000.00
  • MYNZ $895,479.00
  • Revenue This Year
  • RVYL $31.47
  • MYNZ $67.40
  • Revenue Next Year
  • RVYL N/A
  • MYNZ $191.13
  • P/E Ratio
  • RVYL N/A
  • MYNZ N/A
  • Revenue Growth
  • RVYL 78.42
  • MYNZ 69.00
  • 52 Week Low
  • RVYL $1.12
  • MYNZ $0.32
  • 52 Week High
  • RVYL $17.50
  • MYNZ $4.79
  • Technical
  • Relative Strength Index (RSI)
  • RVYL 50.46
  • MYNZ 39.67
  • Support Level
  • RVYL $1.95
  • MYNZ $0.39
  • Resistance Level
  • RVYL $2.25
  • MYNZ $0.46
  • Average True Range (ATR)
  • RVYL 0.22
  • MYNZ 0.08
  • MACD
  • RVYL 0.01
  • MYNZ 0.01
  • Stochastic Oscillator
  • RVYL 37.86
  • MYNZ 26.53

About RVYL Ryvyl Inc.

Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Share on Social Networks: